Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

Investigators from Illumina and Labcorp medical affairs teamed up to perform the largest real-world characterization of advanced non-small cell lung cancer using the TruSight® Oncology 500 (TSO500) assay to date. In our recently published manuscript in Frontiers, we assessed the spectrum of current FDA therapy-associated and clinical trial-associated genomic variants, along with known and novel patterns of co-mutations and co-occurrence with biomarkers predictive of immunotherapy response. We retrospectively analyzed clinical TSO 500 testing data from 7,606 NSCLC  biopsy specimens submitted for testing during standard clinical care. Our data provides further characterization of NSCLC at the genomic and immune checkpoint inhibitor response biomarker level and highlights the clinical utility of broad coverage CGP testing in detecting both known and novel facets of NSCLC to inform treatment decision-making. 

Molecular Tumor Board: 82-year-old female with high grade ovarian serous adenocarcinoma and BRCA1 F709fs mutation

An 82-year-old with advanced high-grade serous ovarian cancer and a BRCA1 mutation highlights the importance of somatic and germline testing to guide therapy and using PARP inhibitors for maintenance. Join our Molecular Tumor Board to explore treatment strategies and the impact of reversion mutations on resistance management.

Graphical Summary: Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

Ask the expert: What you need to know about working with a genetic counselor

Have questions about family genetic health risks or reproductive genetic risks? Genetic counseling can help. Learn more about what genetic counselors do.

Multiple sclerosis monitoring profile

Blood biomarkers (BBMs) are a new frontier in neurology, impacting the way physicians diagnose, manage and monitor neurodegenerative diseases such as Alzheimer’s and ALS. The promise of BBMs, particularly neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), to change and improve multiple sclerosis (MS) patient management is now being realized.

The vital role of the primary care team: Highlights from the AHA Scientific Statement on CKM Syndrome

Cardiovascular disease (CVD), chronic kidney disease (CKD) and diabetes mellitus (DM) are among the most common chronic diseases present in the United States1 and represent 3 of the top 10 leading causes of death.2 These conditions, along with metabolic conditions more broadly, have a significant impact on individual patients as well as on the healthcare system as a whole; furthermore, the prevalence of these conditions is anticipated to increase over the next several decades,3 making the identification and management of these conditions a public health priority. Historically, these conditions have been conceptualized and treated as siloed entities, with each condition being addressed individually. There is increasing appreciation that these common health conditions are closely interconnected from a pathophysiological standpoint and should be approached and treated using a holistic, interdisciplinary approach to achieve optimal patient outcomes. In 2023, the American Heart Association (AHA) issued a scientific statement formally defining the constellation of conditions encompassing CVD, CKD and more broadly, metabolic disease (including diabetes) as cardiovascular-kidney-metabolic (CKM) syndrome and providing recommendations for the clinical management of patients with CKM.4 Both early detection and timely intervention are key to improving health outcomes for patients with CKM syndrome. The primary care team is uniquely positioned to aid in the identification, treatment and monitoring of this recently recognized syndrome.

Biologic drug and anti-drug antibody monitoring: TNF inhibitors infliximab, adalimumab and certolizumab pegol in 128,537 patient samples

Biologic drugs are used to treat auto-immune inflammatory responses associated with IBD. The body may develop anti-drug antibodies against these drugs over time and can be mitigated by ensuring an optimal dosage in patients. This poster details a review of specimens submitted to Labcorp for these drugs and anti-drug antibodies.

Unmasking Crohn’s Disease: Anti-glycan antibodies (ACCA, ALCA, AMCA) may improve diagnostic accuracy while providing prognostic value, especially in ASCA-seronegative patients

Anti-glycan antibodies are found in patients with Crohn’s disease and finding more than one antibody indicates faster progression of the disease. This poster compares the results of these anti-glycan antibodies with a conventional IBD antibody marker.

New blood-based test, 7 alpha-hydroxy-4-cholesten-3-one (7AlphaC4), for bile acid malabsorption/bile acid diarrhea in inflammatory bowel disease or unspecified diarrhea

7AlphaC4 is a test to identify a condition known as bile acid malabsorption. This accounts for about 30% of patients with symptoms of chronic diarrhea and is prevalent in Crohn’s disease patients. This poster details the analysis of specimens tested for 7AlphaC4 at Labcorp and indicates those results.

The value of the norbuprenorphine/buprenorphine (N/B) ratio in Labcorp’s medication-assisted treatment (MAT) urine drug testing

The N/B ratio benefits include:Improved buprenorphine complianceDetection of buprenorphine “pill-dipping”Reduction of buprenorphine misuse and potential diversion